Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study
2025The Lancet Global HealthJournalOpen access
10.1016/s2214-109x(25)00096-8Full text8 citations